| 1. |
Valle JW, Kelley RK, Nervi B, et al. Biliary tract cancer. Lancet, 2021, 397(10272): 428-444.
|
| 2. |
Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin, 2022, 72(1): 7-33.
|
| 3. |
Beal EW, Tumin D, Moris D, et al. Cohort contributions to trends in the incidence and mortality of intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr, 2018, 7(4): 270-276.
|
| 4. |
Saha SK, Zhu AX, Fuchs CS, et al. Forty-year trends in cholangiocarcinoma incidence in the U. S. : intrahepatic disease on the rise. Oncologist, 2016, 21(5): 594-599.
|
| 5. |
Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent, 2024, 4(1): 47-53.
|
| 6. |
Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol, 2020, 17(9): 557-588.
|
| 7. |
Park J, Kim MH, Kim KP, et al. Natural history and prognostic factors of advanced cholangiocarcinoma without surgery, chemotherapy, or radiotherapy: a large-scale observational study. Gut Liver, 2009, 3(4): 298-305.
|
| 8. |
Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med, 2010, 362(14): 1273-1281.
|
| 9. |
Oh DY, Ruth He A, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid, 2022, 1(8): EVIDoa2200015. doi: 10.1056/EVIDoa2200015.
|
| 10. |
Oh DY, Ruth He A, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid, 2022, 1(8): EVIDoa2200015.
|
| 11. |
中華人民共和國國家衛生健康委員會. 原發性肝癌診療指南 (2024年版). 腫瘤綜合治療電子雜志, 2024, 10(03): 17-68.
|
| 12. |
Wang X. et al. A phase Ⅱ trial of hepatic arterial infusion chemotherapy and bevacizumab in combination with toripalimab for advanced biliary tract cancers: Interim report. Ann Oncol, 2022, 33: S568. doi: 10.1016/j.annonc.2022.07.088.
|
| 13. |
Wei Z, Wang Y, Wu B, et al. Hepatic arterial infusion chemotherapy plus lenvatinib with or without programmed cell death protein-1 inhibitors for advanced cholangiocarcinoma. Front Immunol, 2023, 14: 1235724. doi: 10.3389/fimmu.2023.1235724.
|
| 14. |
Huang Y, Du Z, Kan A, et al. Clinical and biomarker analyses of hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitor for patients with advanced intrahepatic cholangiocarcinoma. Front Immunol, 2024, 15: 1260191. doi: 10.3389/fimmu.2024.1260191.
|
| 15. |
Zhao R, Zhou J, Miao Z, et al. Efficacy and safety of lenvatinib plus durvalumab combined with hepatic arterial infusion chemotherapy for unresectable intrahepatic cholangiocarcinoma. Front Immunol, 2024, 15: 1397827. doi: 10.3389/fimmu.2024.1397827.
|
| 16. |
Kim JH, Won HJ, Shin YM, et al. Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma. AJR Am J Roentgenol, 2011, 196(2): W205-W209.
|
| 17. |
Kiefer MV, Albert M, McNally M, et al. Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2-center study. Cancer, 2011, 117(7): 1498-1505.
|
| 18. |
Hyder O, Marsh JW, Salem R, et al. Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis. Ann Surg Oncol, 2013, 20(12): 3779-3786.
|
| 19. |
Ibrahim SM, Mulcahy MF, Lewandowski RJ, et al. Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study. Cancer, 2008, 113(8): 2119-2128.
|
| 20. |
Saxena A, Bester L, Chua TC, et al. Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. Ann Surg Oncol, 2010, 17(2): 484-491.
|
| 21. |
Kim GH, Kim PH, Kim JH, et al. Thermal ablation in the treatment of intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. Eur Radiol, 2022, 32(2): 1205-1215.
|
| 22. |
Kuhlmann JB, Euringer W, Spangenberg HC, et al. Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy. Eur J Gastroenterol Hepatol, 2012, 24(4): 437-443.
|
| 23. |
Al-Adra DP, Gill RS, Axford SJ, et al. Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis. Eur J Surg Oncol, 2015, 41(1): 120-127.
|
| 24. |
Robinson TJ, Du L, Matsuoka L, et al. Survival and toxicities after yttrium-90 transarterial radioembolization of cholangiocarcinoma in the RESiN Registry. J Vasc Interv Radiol, 2023, 34(4): 694-701.
|
| 25. |
Mambrini A, Guglielmi A, Pacetti P, et al. Capecitabine plus hepatic intra-arterial epirubicin and cisplatin in unresectable biliary cancer: a phase Ⅱ study. Anticancer Res, 2007, 27(4C): 3009-3013.
|
| 26. |
Boehm LM, Jayakrishnan TT, Miura JT, et al. Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. J Surg Oncol, 2015, 111(2): 213-220.
|
| 27. |
Konstantinidis IT, Groot Koerkamp B, Do RK, et al. Unresectable intrahepatic cholangiocarcinoma: systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone. Cancer, 2016, 122(5): 758-765.
|
| 28. |
Konstantinidis IT, Do RK, Gultekin DH, et al. Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials. Ann Surg Oncol, 2014, 21(8): 2675-2683.
|
| 29. |
Yang Z, Fu Y, Wu W, et al. Comparison of hepatic arterial infusion chemotherapy with mFOLFOX vs. first-line systemic chemotherapy in patients with unresectable intrahepatic cholangiocarcinoma. Front Pharmacol, 2023, 14: 1234342. doi: 10.3389/fphar.2023.1234342.
|
| 30. |
Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science, 2005, 307(5706): 58-62.
|
| 31. |
Noman MZ, Hasmim M, Lequeux A, et al. Improving cancer immunotherapy by targeting the hypoxic tumor microenvironment: new opportunities and challenges. Cells, 2019, 8(9): 1083. doi: 10.3390/cells8091083.
|
| 32. |
Kato Y, Tabata K, Kimura T, et al. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS One, 2019, 14(2): e0212513. doi: 10.1371/journal.pone.0212513.
|
| 33. |
Zheng S, et al. Lenvatinib enhances antitumor immunity in ICC by reducing immunosuppressive cells. J Immunother Cancer, 2022, 10(5): e004223.
|
| 34. |
Villanueva L, et al. Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase 2 LEAP-005 study. J Clin Oncol, 2021, 39(supply 15): 4080. doi: 10.1200/JCO.2021.39.15_suppl.4080.
|
| 35. |
Finn RS, Ikeda M, Zhu AX, et al. Phase Ⅰb study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol, 2020, 38(26): 2960-2970.
|
| 36. |
Fukumura D, Kloepper J, Amoozgar Z, et al. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol, 2018, 15(5): 325-340.
|
